+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Transarterial Chemoembolization (TACE) Market Size was valued at USD 10.7 Billion in 2022. The Transarterial Chemoembolization (TACE) market industry is projected to grow from USD 11.6 Billion in 2023 to USD 16.6 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.80% during the forecast period (2023 - 2032). Increased drug use and production, as well as increased liver cancer incidence, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
The market for transarterial chemoembolization (TACE) is anticipated to expand as liver cancer cases increase. HCC is the fifth most common type of cancer overall and the second most common cause of cancer mortality in men. High-grade cervical cancer is more common in Asia and Africa. Hepatocellular carcinoma is a primary liver tumor that typically develops as a result of cirrhosis and ongoing liver conditions. Over 500,000 individuals worldwide are impacted by the sickness, which is the third most common global cause of cancer mortality. Transarterial chemoembolization (HCC) is currently the gold standard of treatment for persons with intermediate-stage hepatocellular carcinoma. TACE is therefore thought upon as the accepted course of treatment for HCC.
The procedure of transarterial chemoembolization is used to treat liver cancer. It functions by cutting off the tumor's blood supply. When a supply is interrupted, chemotherapy is administered directly into the tumor. Patients with intermediate-stage hepatocellular cancer get intravenous therapy. The gold standard treatment for HCC is conventional transarterial chemoembolization in the US. It is also possible to use microspheres as drug carriers during transarterial chemoembolization, which could lessen the amount of chemotherapeutics in the patient's systemic circulation.
It is envisaged that novel transarterial chemoembolization products (TACE) and combination therapies (DEB-TACE) may revolutionize how HCC is treated in the upcoming years. The untapped HCC market is anticipated to expand as new medications are made available for both first- and second-line treatments. Following the launch of new products in both first- and second-line settings, the HCC market will expand. New biodegradable microspheres have been developed and are currently being tested to further the TACE technology. They are designed to preserve post-TACE target artery access, opening the door to the prospect of cyclic therapy. TACE is likely to continue to advance in a variety of directions, such as those that are currently "under construction" and focused on improving patient selection, creating new instruments to standardize treatment, increasing selectivity to administer chemotherapeutic agents more precisely while sparing the non-tumor liver, or combining therapies with recently developed immune therapy agents.
New developments in the discipline of selective internal radiation therapy (SIRT) will also have an effect on the future of TACE because indications occasionally overlap. The results of recent research will guide the development of TACE in this era of systemic treatments with unprecedented results and high tolerance. Numerous varieties of micro catheters and micro guidewires are available to meet a range of clinical needs. For instance, the efficacy and safety of the recently found balloon-occluded transarterial chemoembolization (B-TACE) for the treatment of hepatocellular carcinoma (HCC) using gelatin particles and the lipophilic anticancer drug miriplatin. • In a similar vein, hepatocellular carcinoma (HCC) patients who had balloon-occluded transcatheter arterial chemoembolization using a balloon micro-catheter and polyethylene-glycol (PEG) microsphere (100 + 25 m and 200 + 50 m) experienced superior clinical outcomes. Thus, driving the Transarterial Chemoembolization (TACE) market revenue.
The global Transarterial Chemoembolization (TACE) market segmentation, based on Procedure Type, includes conventional TACE and DEB-TACE. Conventional Tace segment dominated the global market in 2022. This can be attributed to the rising incidence of hepatocellular cancer.
The global Transarterial Chemoembolization (TACE) market segmentation, based on Indication, includes unresectable HCC and early-stage HCC. The unresectable HCC segment dominated the global market in 2022. The increased usage of medications and exponential growth account for this.
The global Transarterial Chemoembolization (TACE) market segmentation, based on Product Type, includes chemotherapeutic agents, radiotherapeutic agents, drug-eluting particles, and others. Mitral valve segment dominated the global Transarterial Chemoembolization (TACE) market in 2022. This is a result of the gradually increasing incidence of HCC, which is brought on by smoking and other immune-stressing factors.
The global Transarterial Chemoembolization (TACE) market segmentation, based on End User, includes hospitals & clinics, cancer research centers, and others. The hospital & clinics segment dominated the global Transarterial Chemoembolization (TACE) market in 2022. The increase in hospital operations, favorable government investment, and improved cancer management are the causes of this. Patients at specialized clinics and other market sectors are driving increasing the market value for transarterial chemoembolization (TACE).
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. The North America Transarterial Chemoembolization (TACE) Market dominated this market in 2022 (45.80%). This can be attributed to elements including continually increasing HCC instances, increased investment, the creation of cutting-edge pharmaceutical delivery methods, and the presence of sizable market players in the region. The majority of the leading businesses in the developed regions have made a number of strategic acquisitions, which has gradually increased their market share. Further, In the North American area, the U.S. Transarterial Chemoembolization (TACE) market had the biggest market share, while the Canada Transarterial Chemoembolization (TACE) market had the quickest rate of expansion.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Europe Transarterial Chemoembolization (TACE) market accounted for the healthy market share in 2022. The rising incidence of cancer in the region is one of the key reasons propelling the growth of the transcatheter arterial chemoembolization market. The European chemoembolization market is growing as a result of improved local cancer control, improved treatment outcomes, and advanced ultra-selective TACE, which can be utilized to treat microscopic HCCs. Further, In the European region, the German Transarterial Chemoembolization (TACE) market had the biggest market share, and the U.K. Transarterial Chemoembolization (TACE) market had the quickest rate of growth.
The Asia Pacific Transarterial Chemoembolization (TACE) market is expected to register significant growth from 2023 to 2032. In the Asia Pacific region, TACE with a lipiodol-chemotherapeutic drug suspension and gelatin sponge (GS) particles is widely advertised. Here, there is a huge market for conventional TACE (cTACE). On the other hand, drug-eluting bead-based TACE therapies, such as DEB-TACE (a kind of DEB called DEBDOX that may bind doxorubicin), are strongly recommended. Moreover, In the Asia-Pacific region, the Indian Transarterial Chemoembolization (TACE) market had the quickest rate of growth while China's Transarterial Chemoembolization (TACE) market had the greatest market share.
Leading industry companies are making significant R&D investments in order to diversify their product offerings, which will drive the Transarterial Chemoembolization (TACE) market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants are also engaging in a number of strategic actions to increase their global footprint. The Transarterial Chemoembolization (TACE) sector needs to provide affordable products if it wants to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies employed by manufacturers in the worldwide Transarterial Chemoembolization (TACE) industry to assist customers and expand the market sector is local manufacturing to reduce operational costs. Some of the biggest benefits to medicine have recently come from the Transarterial Chemoembolization (TACE) sector. Major players in the Transarterial Chemoembolization (TACE) market, including Advaxis Inc., Baxter, Bellicum Pharmaceuticals, Boston Scientific Corporation, Cook, Hikma Pharmaceuticals PLC, Isofol Medical AB, Nippon Kayaku Co., Novartis, Pfizer, Sirtex SIR-Spheres Pty Ltd., and Spectrum Pharmaceuticals, are attempting to increase market demand by investing in research and development Products.
The discovery, development, production, and marketing of prescription medications, biologic therapies, vaccines, and animal health products are the sole focus of the biopharmaceutical company Merck & Co Inc (Merck). For the treatment of illnesses like diabetes, cancer, immunological diseases, cardiovascular disease, and cancer, it offers medications that can be obtained with a prescription. In addition to other animal health products, the company sells products for poultry, cattle, and aquaculture. Hospitals, government agencies, distributors, retailers, and hospitals are served by the managed healthcare services offered by Merck. Additionally, it offers animal health products to distributors, producers, and veterinarians. The corporation and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside of North America and Canada, and its head office is located in Kenilworth, New Jersey. Merck Sharp & Dohme LLC and Eisai Inc. released a report in February 2023 titled Update on Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma.
The biopharmaceutical company AstraZeneca Plc (AstraZeneca) specializes in the discovery, production, and marketing of a range of prescription drugs. It produces products to treat diseases like cancer, autoimmune disorders, infectious diseases, neurological disorders, as well as respiratory, cardiovascular, renal, and metabolic issues. The company's product portfolio includes biologics, prescription drugs, and vaccines. AstraZeneca sells its products through distributors, regional representative offices, and completely owned regional marketing businesses. Both general practitioners and medical specialists are the customers of the company. Europe, the Americas, Asia, Africa, and Australasia are among the regions where the company operates. The company's headquarters are in Cambridge, a city in Cambridgeshire, the United Kingdom. In April 2023, AstraZeneca released an update to the study Evaluation of Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1).
· Advaxis Inc.
· Baxter
· Bellicum Pharmaceuticals
· Boston Scientific Corporation
· Cook
· Hikma Pharmaceuticals PLC
· Isofol Medical AB
· Nippon Kayaku Co.
· Novartis
· Pfizer
· Sirtex SIR-Spheres Pty Ltd.
· Spectrum Pharmaceuticals
May 2023: Bristol-Myers Squibb is assessing Nivolumab with Ipilimumab and Nivolumab Alone in Combination With Trans-Arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W).
· Conventional TACE
· DEB-TACE
· Unresectable HCC
· Early-Stage HCC
· Chemotherapeutic Agents
· Radiotherapeutic Agents
· Drug-eluting Particles
· Others
· Hospitals & Clinics
· Cancer Research Centers
· Others
· North America
- U.S.
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 10.7 Billion |
|
Market Size 2023 |
USD 11.6 Billion |
|
Market Size 2032 |
USD 16.6 Billion |
|
Compound Annual Growth Rate (CAGR) |
4.80% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Procedure Type, Indication, Product Type, End User, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Advaxis Inc., Baxter, Bellicum Pharmaceuticals, Boston Scientific Corporation, Cook, Hikma Pharmaceuticals PLC, Isofol Medical AB, Nippon Kayaku Co., Novartis, Pfizer, Sirtex SIR-Spheres Pty Ltd., and Spectrum Pharmaceuticals |
|
Key Market Opportunities |
New product launches |
|
Key Market Dynamics |
Rising incidence of liver cancer and increasing medication usage and development |
The global Transarterial Chemoembolization (TACE) Market was valued at USD 10.7 billion in 2022, and it is estimated to reach USD 16.6 billion by 2032.
The global market is projected to grow at a CAGR of 4.80% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Advaxis Inc., Baxter, Bellicum Pharmaceuticals, Boston Scientific Corporation, Cook, Hikma Pharmaceuticals PLC, Isofol Medical AB, Nippon Kayaku Co., Novartis, Pfizer, Sirtex SIR-Spheres Pty Ltd., and Spectrum Pharmaceuticals
The Conventional TACE Procedure Type dominated the market in 2022.
The Unresectable HCC Indication had the largest share in the global market.
Research on the market is done by industry professionals who provide personalized insights on the industry structure, market segmentation, Type assessment, competitive landscape (CL), along with penetration, and emerging trends. In addition to years of professional experience in their various fields and sectors, their analysis is largely based on primary interview (60%) and secondary research (40%) as well as years of professional experience. In addition, our researchers forecast the market's direction over the following seven years by examining past trends and the market's current position. Additionally, various trends of segments and categories that are geographically portrayed are studied and estimated using primary and secondary research.
The key level executives (VP, CEO, Marketing Directors, and Business Development Managers) of the major industry participants who are active and prominent as well as mid-scale businesses operating in this market were interviewed in-depth for this supply-side report by overall Global Market Research.
Extensive primary research was conducted to gain a deeper grasp of the market and industry. Both primary and secondary research, as well as years of pertinent professional experience, are used to support the analysis. By analyzing past and present market patterns, our experts were able to forecast the market's course over the following seven years. For the geographically offered categories in the list of market tables, it differs per category. In connection with the Global Market research report, we also conducted a number of primary interviews with senior level executives (VP, CEO's, Directors, Marketing Directors, Business Development Managers, CFOs, Technical Consultants, Key Opinion Leaders, Industry Experts, Decision Matrix Authorities, and other crucial individuals) of the key industry players who dominated the Global market.
The primary purpose of secondary research was to gather, identify, and validate the information necessary for the thorough, technical, market-focused, and commercial analysis of the global market. With the use of this study, it was also possible to classify and segment the market in accordance with market trends, geographic markets, and regional considerations linked to market type. Analysts have gathered data in the Distribution Channel for the study of the market from reliable sources including annual reports, journals, white papers, corporate presentations, company websites, international organizations of Energy and Power manufacturers, credible paid databases, and many others to gather reliable intel.
Both top-down and bottom-up methodologies were employed to assess the accuracy of the global market size. The market for as a whole was estimated using these methods for a number of different dependent submarkets. Secondary research was used to address the major industry players, and primary and secondary research was used to calculate their market shares in the various regions. This complete intellectual process includes reading the annual and financial reports of the top market participants and conducting in-depth interviews with top industry executives (VP, CEO, Marketing Directors, and Business Development Managers) to gain important industry insights.
Through reliable secondary sources and validated primary sources, the classification of the global markets and their geographic percentage splits were established. To obtain the final qualitative and quantitative data, all relevant variables that might have an impact on the market under investigation have been taken into consideration, inspected in great depth, verified through primary research, and assessed. This information was collected, added to, and thoroughly examined by professional analysts before being provided in this report. The process used to estimate the overall market size for this study is depicted in the following image as an example.
Report Code :
RL65219
Published on :
Sep 2023
Request a Free Sample Report
Speak to Analyst